Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 12/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033808 | 0.83 | PYCR1 (0.55) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL10033801 | 0.82 | PYCR1 (0.79) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL10033812 | 0.78 | PYCR1 (0.48) | PYCR1ACHE | |
| SCHEMBL13756311 | 0.74 | BCL2 (0.71) | LMNAALDH1A1LTB4R2KMO | |
| SCHEMBL10243325 | 0.74 | BCL2 (0.71) | LMNAALDH1A1LTB4R2KMO | |
| Trimethylammonium SCHEMBL27623058 | 0.74 | KMO (0.81) | LMNATSHRKMO | |
| SCHEMBL14683877 | 0.73 | KMO (0.87) | LMNAKMO | |
| SCHEMBL29577419 | 0.73 | KMO (0.87) | LMNAKMO | |
| SCHEMBL5154732 | 0.73 | KMO (0.67) | LMNALTB4R2KMO | |
| SCHEMBL1855849 | 0.73 | KMO (0.67) | LMNAKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2008092091-A2 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | MAOA, MAOB, PNMT | PYCR1 975/4885LMNA 1769/4885MAOB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.